Recent changes to adult Pneumococcal Pneumonia Vaccine recommendations
This announcement has 2 attachments:
I want to make you all aware of the new guidelines for immunizing adults against pneumococcal pneumonia. These attachments are quick reference guides to help you, please access the CDC website for further info. Thanks, Julie Hannah, FNP-C
TIMELINE OF CHANGES IN PNEUMOVAX RECOMMENDATIONS:
• In 2010, the Advisory Committee on Immunization Practices (ACIP) recommended that all persons should be vaccinated with 23-valent pneumococcal polysaccharide vaccine (PPSV23) at age 65 years.
• In 2011, PCV13 was approved by the FDA for adults aged ≥50 years.
• In 2012, ACIP recommended use of 13-valent pneumococcal conjugate vaccine (PCV13) and PPSV23 for adults aged ≥19 years with immune-compromising conditions (see attachment).
• In June 2014, the results of a randomized placebo-controlled trial showing efficacy of PCV13 against community-acquired pneumonia among adults aged ≥65 years were presented to ACIP.
• In September 2014, the ACIP recommended that both PCV13 and PPSV23 should be routinely administered in series to all adults aged ≥65 years (see attachment).